168162-28-5

Basic information

• Product Name: 3-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID METHYL ESTER
• Synonyms: 3-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID METHYL ESTER;Methyl 3-(2-oxopiperidin-1-yl)benzoate
• CAS NO: 168162-28-5
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.2631
• Mol File: 168162-28-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID METHYL ESTER(168162-28-5)
• EPA Substance Registry System: 3-(2-OXO-PIPERIDIN-1-YL)-BENZOIC ACID METHYL ESTER(168162-28-5)

Safety Data

• Hazardous Substances Data: 168162-28-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
3-(2-Oxo-piperidin-1-yl)-benzoic acid methyl ester is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with potential therapeutic applications.
Used in Drug Development:
3-(2-Oxo-piperidin-1-yl)-benzoic acid methyl ester is used as a lead compound in drug discovery and development. Its structural features can be further modified to optimize its pharmacological properties and enhance its therapeutic potential.

Upstream product

• 99-05-8 meta-aminobenzoic acid 
• 39716-58-0 pent-4-enoyl chloride 
• 591-80-0 pent-4-enoic acid 
• 4518-10-9 Methyl 3-aminobenzoate 
• 168162-27-4 methyl 3-(5-bromopentanoylamino)benzoate 
• 168162-37-6 3-(5-Hydroxy-pentanoylamino)-benzoic acid methyl ester 
• 168162-26-3 methyl 3-(4-pentenoylamino)benzoate 

Downstream Products

• 1016744-53-8 3-(2-oxopiperidin-1-yl)benzoic acid 
• 77940-94-4 3-(1-Piperidinyl)benzoic acid 
• 57489-59-5 3-piperidin-1-yl-benzoic acid methyl ester 

Relevant articles and documents

Process of preparing benzodiazepine compounds useful as antagonists of CCK or of gastrine

A benzodiazepine derivative of formula I, or a pharmaceutically acceptable salt thereof: STR1 wherein: (a) R4 is an alkyl, cycloalkyl or aryl group. (b) R10 is chosen from halo, OH, CH3, OCH3, NR11 R12, NO2, NHCHO, CO2 H and CN, and R11 and R12 are independently selected from H and alkyl (C1 -C5) or together NR11 R12 form a cyclic structure II, STR2 wherein a is 1-6; and (c) R2 is an aromatic 5- or 6-membered, substituted or unsubstituted heterocycle containing at least two heteroatoms of which at least one is nitrogen. These compounds are gastrin and/or CCK-B receptor antagonists.

(3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)- 1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): A potent and orally active gastrin/CCK-B antagonist

A number of new 1,4-benzodiazepin-2-one-based gastrin/CCK-B receptor antagonists related to the archetypal analogue L-365,260, and more closely to the recently reported compound YM022, have been synthesized and evaluated for biological activity. The compounds were screened for their ability to inhibit the binding of [125I]CCK-8 to gastrin/CCK-B receptors prepared from rat brains and that of [3H]L-364,718 to CCK-A receptors from rat pancreas, and were shown to be potent and selective ligands for the gastrin/CCK-B receptor. Functional studies in vivo demonstrated the compounds to be antagonists of the receptor as evidenced by their ability to inhibit pentagastrin-induced gastric acid secretion in anesthetized rats. More extensive evaluation in viva included determination of ED50 values in the rat acid secretion model for selected compounds and an examination of the effect of these compounds on pentagastrin-induced gastric acid secretion in Heidenhain pouch dogs following oral and intravenous administration. Two compounds, i.e. (3R)-N- [1-[(tert-butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl]-N'-[3-(methylamino)phenyl]urea, 15c (YF476), and (3R)-N- [1-[(tert-Butylcarbonyl)methyl]-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4- benzodiazepin-3-yl]-N'-[3-(dimethylamino)phenyl]urea hydrochloride, 15d, showed potent dose-dependent effects in both models with the former showing excellent oral bioavailability and an ED50 of 21 nmol/kg po in dogs. 15e is currently under clinical investigation for the treatment of gastro-oesophagal reflux disease (GORD).